Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: The use of combination epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) and immune checkpoint inhibitor (ICI) in EGFR-mutant, advanced non-small cell lung cancer (NSCLC) has raised concerns over the risk of overlapping toxicities. Although a higher proportion of interstit...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Daisy Wai-Ka, Choi, Horace Cheuk-Wai, Lee, Victor Ho-Fun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102470/
https://www.ncbi.nlm.nih.gov/pubmed/35565285
http://dx.doi.org/10.3390/cancers14092157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102470/
https://www.ncbi.nlm.nih.gov/pubmed/35565285
http://dx.doi.org/10.3390/cancers14092157

Ejemplares similares